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Antibodies against Epstein-Barr
nuclear antigen (EBNA) in multiple
sclerosis CSG and two pentapepfide
seauence identities between EBNA
and myelin basic protein
A

Patrick F. Bray, MD; J. Luka, PhD; Paul F. Bray, MD; K.W. Culp, BS; and J.P. Schlight, BS

Article abstract-The Epstein-Barr virus (EBV) causes infectious mononucleosis and is linked to several disparate
malignancies. Prior studies on patients with multiple’sclerosis (MS) showed that 100% are EBV-seropositive and that
their blood contains higher antibody titers than those of controls to both transformation and lytic cycle antigens. We
performed three different assays for antibodies in CSF to three major EBV antigens from patients with MS and controls. Among 93 patients with MS, 79 (85%)had CSF that reacted with a 70 kD protein, shown to be the nuclear antigen, EBNA-1, whereas only 11(13%)of 81 EBV-seropositive controls reacted, p < 0.001. The CSF of all 14 MS patients,
unreactive on immunoblots, contained oligoclonal bands on agarose electrophoresis. Together, the two techniques
exhibit 100% sensitivity in the confirmatory diagnosis of MS. We also performed amino acid searches of the Protein
Identification Resource sequence database for protein homologies to EBNA. Two pentapeptide identities were found
between EBNA-1 and myelin basic protein: QKRPS and PRHRD. None of more than 32,000 other proteins in the
database contained both pentapeptides. In healthy EBV-seropositive persons, the EBV-specific, MHC-restricted T lymphocytes keep the EBV-containing B lymphocytes locked in the transformed state. However, in the host genetically
susceptible to MS, the same population of lymphocytes might recognize and interact with either of the two identified
pentapeptides, inadvertently damaging MBP.
NEUROLOGY 1992;42:1798-1804

Burkitt’s original epidemiologic observations suggested a role for an infectious agent in the pathogenesis of the jaw tumor, Burkitt’s lymphoma
(BL), which affects children living in the endemic
malaria belt of central Africa.l Epstein et a12 first
observed the virus with the electron microscope in
tumor cells cultured from p a t i e n t s with BL.
Subsequently, Henle et a13 and Niederman et a1,4
using vigilant clinical observations and extensive
seroepidemiologic methods, showed t h a t t h e
E p s t e i n - B a r r v i r u s (EBV) causes infectious
mononucleosis. Worldwide studies have shown
that all biopsies from undifferentiated nasopharyngeal carcinoma tumor cells contain EBV DNA
in varying q ~ a n t i t i e s The
. ~ critical role of host
immune mechanisms in responding to a n EBV
infection is dramatically exemplified by the EBV-

associated diseases in humans, including lymphoproliferative disorders i n p a t i e n t s who a r e
immunosuppressed therapeutically,6 opportunistially,^ or genetically.s
Multiple sclerosis (MS), the most common progressive demyelinating disease in the economically
privileged western world, has been recognized as a
clinicopathologic entity for more than 150 years.
The cause and pathogenesis remain unclear, but
one finds a consensus that abnormalities in both
humoral and cellular immunity occur consistently.
Kurtzkeg and Kurtzke and HyllestedlO have carried out extensive epidemiologic studies, including
(1)planetary incidence and prevalence surveys, (2)
prevalence of MS in migrants, and (3) epidemics in
the Faroe Islands and Iceland. They have suggested t h a t one or more environmental factors may
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influence pathogenesis; K u r t z k e g has s t a t e d , “If
these findings (epidemics among the Faroese and
Icelanders) are valid, both would indicate the definition of MS as not only an acquired disease b u t
also a transmittable one.” However, despite years of
effort to incriminate a causal environmental factor,
no agent has been recovered consistently from, or
seen in, affected CNS tissue. Nor has t h e disease
ever been transmitted to experimental animals.
U s i n g seroepidemiologic data, S u m a y a et all1
w e r e a m o n g the first t o suggest an association
between MS and EBV infection. Later, we assayed
blood samples from MS subjects a n d controls, measuring seropositivity rates and antibody concentrations t o seven common viruses.12 Comparing MS
and control populations, we found a highly significant difference only for EBV. MS patients showed
100% seropositivity compared with 89% for ageand sex-matched controls ( p < 0.0001).13S e r u m
antibody titers against viral capsid antigen (VCA)
were five t o six times higher, a n d against the
nuclear antigen (EBNA) t h e y were three to four
times higher, at the same level of statistical significance ( p < 0.0001).13J4
Recently, we observed five patients with a neurologically complicated p r i m a r y EBV infection, in
whom four (followed from 4 to 12 years) developed
MS, and o n e had a c u t e disseminated encephalomyelitis that left her, after a 2-year follow-up, with
permanent neurologic deficits. l5
The association between EBV blood seropositivity and MS, along with t h e aforementioned clinical
association b e t w e e n p r i m a r y EBV infection and
d e m y e l i n a t i n g disease, p r o m p t e d us t o conduct
studies on the CSF of MS and control patients. We
performed assays of antibodies against the latencyassociated antigen, EBNA, and against the lytic
cycle antigens, VCA a n d e a r l y a n t i g e n - d i f f u s e
(EA-D), in M S and neurologic d i s e a s e c o n t r o l s
(NDC). We also carried out searches for amino acid
sequence identities between myelin basic protein
(MBP) and all other proteins listed in a national
protein sequence database.

Methods. Clinical patient selection. The diagnosis and
available laboratory findings were individually reviewed
in a group of 246 patients. A neurologic or neuropsychiatric diagnosis was under consideration in all these
patients, and so a CSF examination was performed. MS
patients were included in the study only if two or more
neurologists considered the diagnosis clinically definite.
A clinical diagnosis of MS was made only if the neurologic disorder met standard criteria.16J7 Confirmatory tests
included the established methods for immunoglobulin
analysis and brain imaging procedures. No patient was
included in the study unless the blood-brain barrier
(BBB) was intact, as determined by the ratio of CSF
albumidserum albumin. l8
Each NDC patient received the same clinical and laboratory scrutiny. Subjects were included in this category
only if their serum EBV antibody profile was positive, if
they had an intact BBB, and if demyelinating disease
was excluded. The diagnostic spectrum of this group
ranged from patients with stroke, progressive nonde-

myelinating degenerative disorders, psychiatric disorders, tumor, and infectious-inflammatory diseases,
excluding known primary EBV infections, to any patient
who presented with complaints referable to the nervous
system and in whom the neurologist considered a CSF
examination advisable.
Laboratory techniques. Quantitative and qualitative
analyses of CSF k G . Approximately 95% of patients
with the diagnosis of clinically definite MS exhibit an
increased CNS synthesis of IgG or the presence of oligoclonal bands (OCB) in their CSF.19 OCB were identified
by agarose gel electrophoresis.20
Cell lines. We used several cell lines as sources for the
different EBV viral antigens. The BL-derived, non-virusproducing Raji cell line carries the EBV genome and is
known to express EBNA-1 constitutively.z1 The virusproducing line, P3HR1, was used as a source of VCA.z2
Raji cells superinfected with virus produced from the
P3HR1 cell line were used as a source for expression of
EA-D protein.zz An EBV-genome-negative BL cell line,
designated BJAB, was used as a negative control.
Anticomdement immunofluorescence (ACIF). Using
P3HR1 cells, we employed serial dilutions of CSF to
identify antibodies to VCA, as described
Enzyme-linked immunosorbent assays (EIA). EIAs
were performed using purified EBV EBNA-IgG proteinz3
and purified EBV VCA-IgG protein22-26
(generously provided by Ortho Diagnostics Systems, Inc.) as target antigens and CSF a s the antibody source. Methodologic
details were performed according to the manufacturer’s
instructions. Preliminary experiments revealed that a
1:10 dilution distinguished best between background
activity and specific antibody in both control and MS
CSF samples.
Western immunoblots. P3HR1, Raji, and BJAB cells
were washed in phosphate-buffered saline, which is
0.136 M NaC1, 2.68 mM KC1, 10 mM Na,HPO,, and 1.76
mM KH,PO,, pH 7.4. Cells were solubilized in 2% sodium dodecyl sulfate (SDS), and 15 bg of protein was separated by SDS-polyacrylamide gel electrophoresis (SDSPAGE) and transferred t o nitrocellulose sheets.27The
sheets were cut into strips and incubated with individual
CSF samples as the primary antibody in a final volume
of 0.6 ml. The amount of IgG in each CSF sample was
standardized to IgG 1.0 mg/dl in 0.5% bovine serum
albumin/0.05% Tween-20 in phosphate-buffered saline.
Control sera came from individuals with high-titer antibodies to EBNA-1, as assayed by ACIF. In some experiments, a monoclonal antibody specific for the EA-D antigen was used a s t h e primary antibody in the immunoblots.22
Analyses on the 70 kD protein. Cell extracts for
immunoblotting and peptide mapping were performed by
sonicating 2 X lo8 Raji cells in a buffer containing 150
mM NaC1, 20 mM TRIS-HC1, pH 7.4, 10 mM NaF, 1 mM
phenyl methyl sulfonyl fluoride, and 1 mM P-mercaptoethanol. The extract was clarified by centrifugation in a
Sorvall centrifuge at 20,000 x g for 1 hour. The supernatant was removed from the pellet and was heat-treated at 70 “C for 10 minutes to precipitate heat-labile proteins. Then the heat-precipitated proteins were pelleted
at 10,000 X g for 15 minutes. The supernatant was used
in SDS-PAGE for immunoblotting, either without further
t r e a t m e n t o r a f t e r incubation with 10 pg/ml chymotrypsin (Sigma, Type VII-TLCK treated) at 37 “C for
12 hours.
Protein sequence homologies between EBNA-1 and
human mvelin basic motein. Using the FASTA program,
September 1992 NEUROLOGY 42 1799

we searched the Protein Identification Resource (PIR)
sequence database, version 29.0, for amino acid sequence
identities between MBP and all other proteins of defined
sequence.28

Results (figure 1).Anti-EBNA-1 IgG CSF antibodies (EIA and immunoblots). To identify possible
anti-EBV antibodies in CSF samples, we performed
EIAs, using purified EBNA-1 protein as the target
antigen.
Using Ortho’s high-titer positive and negative
serum controls,.we measured antibodies to EBNA-1
and VCA i n t h e study a n d control populations.
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Figure 1. Summary of Epstein-Burr virus CSF antibody
data in patients with multiple sclerosis and neurologic
disease controls.

Among the MS patients, 35 of 50 (70%)of the CSF
samples were EIA-positive compared with eight of
50 (16%) NDC, results that differed significantly: x2
= 29.74, df 1,p c 0.001 (figure 1).These results
suggested the presence of a protein in the CSF of
patients with MS t h at reacted with the EBNA-1
protein in this assay.
To rule out t h e possibility of a contaminating
immunoreactive, non-EBNA-1 antigen in the EIAs,
we then performed Western immunoblots on both
untreated and heat-treated Raji cell extracts using
whole CSF as the primary source of antibody. An
additional group of 174 MS and NDC patients was
studied. The results of the CSF immunoblot analyses from these patients are also summarized in figure 1. Among the CSF samples from patients with
MS, 79 of 93 (85%) exhibited a 70 kD protein, and
14 of 93 (15%) were negative. Seventy of 81 (87%)
NDC samples were unreactive, and 11 of 81 (13%)
did react.
A typical sampling of these results is seen in figure 2. Lanes A and B contain sera from healthy controls, which reacted with a 70 kD protein. Five of
the 10 CSF samples, all from patients with the clinical diagnosis of MS, also react ed wi t h a comigrating 70 kD protein (lanes C, D, F, G, and K).
The CSF from five NDC (lanes E, H, I, L, and M)
did not react. These results support the findings of
the EIA, indicating that this antibody in the CSF
reacts with a heat-stable protein. EBNA-1 is known
to migrate with a Mr-70 kD protein in SDS-PAGE.
To rule out the possibility of a coincidentally comigrating protein, we sought supporting evidence
t h at the 70 kD protein was, in fact, EBNA-1. We

Figure 2. Immunoblots of
heat-treated Raji cell
lysates with CSF samples
and control sera. Cell
extracts were applied to
an 8% sodium dodecyl
sulfate-polyacrylamide
gel, electrophoresed, and
transferred to Immobilin
Ppaper. The strips were
exposed to antiEBNA-positive human
serum (lanes A and B)
and to various CSF
samples (lanes B through
M). The 70 kD protein is
indicated by the arrow.
Samples from patients
with multiple sclerosis
are shown in lanes C, D,
F, G, and K. Neurologic
disease control samples
appear in lanes E, H, I,
L, and M .
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Figure 3. Immunoblots of heat-treated and chymotrypsindigested Raji cell extracts. Treated extracts were applied
to a 10% sodium dodecyl sulfate polyacrylamide gel,
electrophoresed, and transferred to Immobilin P paper.
The 40 kD peptide is indicated by the arrow. The serums
and CSF samples are identical with and appear in the
same alphabetized lane sequence as those shown in figure
2.

incubated the Raji cell extracts with chymotrypsin
to determine a limited peptide map of the 70 kD
protein. Figure 3 shows the results obtained when
CSF was reacted with these digested Raji cell
extracts. As in figure 2, the same two positive sera
and five MS CSF samples reacted, but with a
smaller peptide of Mr-40 kD. The NDC, as in figure 2, did not identify this fragment.
Anti-VCA CSF IgG antibody (ACIF and EIA).
Previous work by us, using the Raji cell line, has
shown that the VCA antigen (160 kD) cannot be
detected by Western blotting (unpublished observations). In the standard serum assay for identification of anti-VCA antibodies, ACIF is performed on
P3HR1 cells. We modified this procedure by using
CSF as the antibody source. Antibodies to VCA
were present in 32 of 47 (68%) MS CSF samples
and in 12 of 55 (22%) NDC (figure 1). Geometric
mean titers of anti-VCA from 77 patients with MS
and 41 NDC, respectively, were 2.79 compared
with 1.41 in CSF, and 292 compared with 218 in
serum. The two groups differed statistically but the
absolute differences were small: CSF x2 = 22, d f 3, p
< 0.001; serum x2 = 18.5, df 44, p < 0.001. The BBB
had no influence on the statistically higher concentrations in the MS population: r = 0.00 (Pearson’s
correlation coeffi~ient).~~

Figure 1 shows that on EIA, 24 of 50 (48%) MS
CSF samples contained anti-VCA antibodies compared with 14 of 50 (28%) NDC t h a t exhibited
seropositivity, results that differed slightly from
one another: x2 = 4.24, 1d f , p < 0.05.
Anti-EA-D antibody (immunoblots and ACIF).
To detect antibodies against the EA-D antigen, we
probed superinfected Raji cells by using CSF on
Western blots, as above. A monoclonal antibody
specific for EA-D was used t o identify its position
on the filter. We studied 50 additional CSF specimens, 26 samples from M S and 24 from NDC
patients.The CSF from one patient with MS and
two NDC patients reacted with a peptide t h a t
comigrated with the protein identified by the monoclonal anti-EA-D antibody (figure l), findings that
appear insignificantly different.
ACIF has been performed on 177 CSF specimens, mostly from MS and NDC patients. EA-D
was measurable in only one sample, from a patient
with a primary T-cell brain lymphoma (unpublished observations).
CSF OCB and immunoblot data. Of note is that
all 14 MS patients who lacked antibodies in their
CSF to EBNA-1 on immunoblot assays demonstrated CSF IgG OCB on agarose electrophoresis. By
contrast, the 11 NDC patients who were antiEBNA antibody-positive had normal CSF quantitative and qualitative IgG. No obvious clinical differences in the 14 MS patients whose CSF was antiEBNA-negative were found when compared with
the MS population as a whole. We conclude that, in
this study, by applying a combination of agarose
electrophoresis and immunoblotting, we have been
able to identify 100%of MS patients.
Protein sequence identities between EBNA-1 and
MBP. The finding of an anti-EBNA-1 antibody in
the CSF of 85% of our patients with MS led us t o
a s k whether a n y protein similarities existed
between EBNA-1 and MBP in view of the fact that
the latter is conspicuously lost or damaged in the
CNS of patients with MS. We used the FASTA program to search the PIR sequence database for identities (see Methods). Short identical matches were
found for two separate five-amino-acid sequences
between EBNA-1, a protein containing 641 amino
acids, and human MBP, a protein containing 169
amino acids. Using the conventional one-letter
amino acid code,30we found two separate pentapeptides, QKRPS a n d PRHRD. QKRPS corresponds to published amino acid positions 74 to 78
in EBNA-1 and 3 to 7 in MBP. PRHRD corresponds
t o published amino acid positions 64 to 68 in
EBNA-1 and 30 to 34 in MBP.31,32
The FASTA program was then used t o search
the PIR database for amino acid sequences containing both QKRPS and PRHRD. Among approximately 32,000 proteins i n t h e database, only
EBNA-1 and MBP contained both sequences.
Discussion. Our data show t h a t t h e CSF of
patients with MS, when compared with controls,
September 1992 NEUROLOGY 42 1801

contains excessive amounts of antibodies directed
against EBNA-1. Several lines of evidence indicate
t h a t these antibodies are specific for EBNA-1.
First, elevated anti-EBNA-1 titers in the CSF were
detected in an EIA using purified EBNA-1 as the
target antigen. Second, CSF reacts with a 70 kD
protein on Western blots of Raji cells, which are
known to express EBNA-1, and 70 kD is the expected Mr of EBNA-1.22Unlike over 80% of the cellular
proteins that are heat-aggregated at 70°C, EBNA-1
remains soluble at this t e m p e r a t ~ r e as
, ~ ~does the
peptide we have identified on Western immunoblots. Third, Hennessy and KiefP4have shown that
EBNA-1 contains a domain that includes a glycinealanine copolymer. Although this region cannot be
cut or digested by many proteases (personal observations, J. Luka), digestion by chymotrypsin yields
a 40 kD immunoreactive fragment containing the
glycine-alanine copolymer typical of EBNA-1 in
Raji cells. The unique glycine-alanine repeating
sequence migrates as a -40 kD peptide on SDSPAGE and will react with anti-EBNA-1 positive
sera. It has been shown in the general population
that nearly 100% of the anti-EBNA antibody-positive human sera recognize this domain, so this proteolytic cleavage fragment can be used for identification of anti-EBNA-1 a n t i b o d i e ~ When
. ~ ~ chymotrypsin was used to digest the Raji cell extracts,
the CSF samples from patients with MS reacted
with a 40 kD peptide. Taken together, these data
strongly support t h e presence of excessive
anti-EBNA-1 antibody in the CSF from patients
with MS.
The results presented in this report can be
viewed arbitrarily from two vantage points-one
with a view toward possible mechanisms involved
in the pathogenesis of MS and one with minor diagnostic implications.
For more than a generation, many investigators
studying MS have been devoted to the idea that
demyelination results from an autoimmune process. Several lines of evidence support this belief.
First, the classic animal model for T-cell-mediated
autoimmune disease, experimental allergic
encephalomyelitis (EAE), has an almost identical
histopathologic resemblance to MS. However, there
are crucial differences between EAE and MS. The
former is an artificially induced paralytic disorder
that develops in animals that have been injected
with a major protein constituent of myelin, whereas MS is a naturally occurring disease of humans
in which genetic and environmental factors are
incompletely understood. Second, at least 13 different viruses share limited amino acid sequence
homology with human MBP.36,37
Third, within the
past few years a series of report^^^-^^ has shown
that T cells isolated from. MS patients react with
restricted synthetic peptides derived from the MBP
sequence. These observations, along with the ability of T cells taken from animals with EAE to prevent or reverse EAE by vaccination of unaffected
animals, have reinforced the suspicion that T lym1802 NEUROLOGY 42 September 1992

phocytes play an essential role in the process of
d e m y e l i n a t i ~ n Precisely
.~~
how the demyelination
process is set in motion is still unclear.
Although it is possible, but unlikely, that the
anti-EBNA-1 specific antibodies are involved in
the pathogenesis of MS, our finding of amino acid
sequence identities between EBNA-1 and MBP
suggests a mechanism compatible with the central
role of the T lymphocyte. It has been reported by
Zamvil e t a143that a nine-amino-acid residue of
murinehuman MBP is required to induce EAE. Of
particular interest in the latter study is that the
EBNA-1 pentapeptide, QKRPS, is contained within
the nine-amino-acid sequence identified in the
encephalitogenic epitope of MBP.
Ota et a141 were unable to demonstrate that a
peptide containing the first 20 residues of MBP
induced reactivity in T-cell clones responsive t o the
entire MBP protein. Although we have no conflicting data, we can postulate several possible explanations of why the QKRPS sequence could be
pathogenic. First, a synthetic 20-amino-acid peptide from this region may not assume the same secondary a n d t e r t i a r y s t r u c t u r e a s t h e native
molecule. Second, t h e i n vitro manipulations
required to generate T-cell clones reactive to MBP
may not reflect an accurate representation of the in
vivo response. Third, as pointed out by Zamvil et
al,43production of EAE in the mouse requires the
acetylation of the amino terminus of the peptide
containing residues 1to 9 of MBP. Ota et a1 did not
describe this acetylation modification in the first
20-amino-acid residue they synthesized from
MBP.41Fourth, the highly basic region of EBNA-1
could conceivably induce charge-dependent crossreaction to MBP. Finally, it is not unreasonable to
speculate that a heterogeneous group of molecular
defects causes the MS phenotype.
Our observation of modest elevations in both
blood and CSF anti-VCA antibodies may be relevant in the light of Rickinson's in vitro studies44of
EBV-transformed B cells. He and his coworkers
have shown that although most B cells remain permanently locked in the transformation cycle, a
small percentage of cells enters the lytic cycle,
releasing virus particles. If this mechanism occurs
in vivo, one would expect the production of antiVCA antibody.
The diagnosis of MS remains clinical because no
specific laboratory test has yet been developed.
Nevertheless, it is now known that approximately
95% of patients with MS exhibit an increased quantity or an abnormal quality (OCB) of IgG in their
CSF on agarose gel electrophoresis, the simplest
technique for the routine diagnostic laboratory. The
authors readily acknowledge that qualitative IgG
changes may be demonstrable in almost 100% of
MS CSF if SDS-PAGE or sensitive immunofixation
techniques, r a t h e r t h a n agarose, a r e used.
However, our experience at this time convinces us
t h a t these more sensitive methods, as well a s
Western blots, require interpretation by an expert

devoted t o the study of CSF immunoglobulins.
As a rule, in healthy EBV-seropositive persons,
the EBV-specific, class 11, MHC-restricted T lymphocytes keep the EBV-genome-containing B cells
locked in the transformed state. However, in the
host genetically susceptible to MS, the same population of T cells could recognize and interact with
either of the highly charged epitopes, QKRPS or
PRHRD, inadvertently damaging MBP. Further
studies will be required to address this hypothesis.
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